Table 3.

Patient characteristics of treatment-related death

	Treatment-related death (n = 176)
	n	Mortality (%)
Gender
Male	115	1.5
Female	61	1.0
Age (years)
≤64	89	1.0
≥65	87	1.8
Performance status
0–2	150	1.1
3–4	26	5.2
Tumor type
NSCLC	48	1.1
Colorectal	30	1.3
SCLC	29	1.5
Gastric	28	2.2
Malignant lymphoma	14	2.6
Ovarian	16	0.7
Cervical	7	1.1
SCC of the skin	2	11.1
Breast	0	0
Others	2	0.5
Tumor stage
I, II	13	0.9
III, IV	150	1.3
Unknown	13	1.3
Prior chemotherapy
No	53	1.1
Yes	123	1.4
Prior radiotherapy
No	133	1.2
Yes	42	1.4
Unknown	1	0.6
Pleural effusiona
No	148	1.2
Yes	24	2.2
Unknown	4	0.7
Massive ascitesa
No	152	1.2
Yes	20	3.1
Unknown	4	0.7
Watery stoola
No	172	1.3
Yes	1	1.0
Unknown	3	0.6
Infectiona
No	164	1.2
Yes	9	4.6
Unknown	3	0.5
Jaundicea
No	162	1.3
Yes	3	3.9
Unknown	11	1.0
Ileusa
No	173	1.3
Yes	2	5.1
Unknown	1	0.4
Concurrent diseases at the start of treatment
No	102	1.0
Yes	73	1.9
Hepatic dysfunctionb	14
Renal dysfunction	20
Diabetes mellitus	4
Heart disease	13
Unknown	1	0.6
Chemotherapy
Irinotecan alone	53	1.6
Combination	123	1.2
Combination therapy with radiation
No	161	1.2
Yes	15	1.6
Total no. of doses
1–3	118	2.2
4–	58	0.7
1	48
2	57
3	13

^aAt the beginning of irinotecan treatment.

^bMain concurrent diseases.